Healthy Skepticism Library

Items published during the years 1990 to 1999

There are 2362 items in the Healthy Skepticism Library that were published during the years 1990 to 1999.

Page 19 of 24 pages ‹ First  < 17 18 19 20 21 >  Last ›

HSL4321
Camerlain M.
Three cheers for CME
Canadian Medical Association Journal 1992; 146:1153

HSL4324
Caudill TS, Lurie N, Rich EC.
The influence of pharmaceutical industry advertising on physician prescribing
Journal of Drug Issues 1992; 22:331-338

HSL4325
Cearnal ME.
Medical marketing communications today: Use and abuse
Journal of Pharmaceutical Marketing & Management 1992; 7:(1):23-32

HSL4326
Chetley A, Mintzes B.
Promoting health or pushing drugs?
Health Action International 1992
www.haiweb.org

HSL4328
Chren MM.
The need for guidelines about pharmaceutical promotions involving gifts to physicians
Journal of Pharmaceutical Marketing & Management 1992; 7:(1):135-145

HSL4329
Cooper RM.
The Food and Drug Administration's authority to regulate miscellaneous statements by pharmaceutical manufacturers
Journal of Pharmaceutical Marketing & Management 1992; 7:(1):99-120

HSL4330
Cope JD.
Nonprescription drugs and the regulation of advertising
Journal of Drug Issues 1992; 22:257-264

HSL4331
American Medical Association.Council on Ethical and Judicial Affairs.
Guidelines on gifts to physicians from industry: an update
Food Drug Law J. 1992; 47:(4):445-58

HSL4332
Cundy T.
Medical junk mail
New Zealand Medical Journal 1992; 105:437

HSL4333
Data JL, Barton KS.
Advertising baldly to the public
New England Journal of Medicine 1992; 326:330-331

HSL4334
Davis P.
The pharmaceutical industry: a valuable CME resource
Canadian Journal of CME 1992; 4:(8):1-2

HSL4335
Demarco T.
Should physicians pay for medical journals
Canadian Family Physician 1992; 38:1769

HSL4336
Dickersin K, Min YI, Meinert CL.
Factors influencing publication of research results: Follow-up of applications submitted to two institutional review boards
JAMA 1992; 267:374-378

HSL4337
Ende M.
Pharmaceutical promotion
New England Journal of Medicine 1992; 327:1687

HSL4338
Ferner RE, Scott DK.
The nature and content of advertisements for medicines
British Journal of Clinical Pharmacology 1992; 34:158P

HSL4339
Fink E, Antonelli MA.
Pharmaceutical ads in Annals
Annals of Internal Medicine 1992; 116:958

HSL4341
Forrest JV.
Pharmaceutical promotion
New England Journal of Medicine 1992; 327:1687

HSL4342
Freedman M.
Physicians and pharmaceutical companies
Canadian Medical Association Journal 1992; 146:329

HSL4345
Gans JA.
The need for guidelines in pharmaceutical promotion: A pharmacy perspective
Journal of Pharmaceutical Marketing & Management 1992; 7:(1):147-155

HSL4346
Girard DE.
The relationship between physicians in training and pharmaceutical companies: A time for guidelines?
Archives of Internal Medicine 1992; 152:920-921

HSL4348
Goertzen J.
Inappropriate layout?
Canadian Family Physician 1992; 38:1769

HSL4350
Gurnee MC, Hansen JM, Sylvestri MF.
Portrayal of the elderly in drug product advertisements: Relationship to dosing recommendations and pharmacokinetic data in the geriatric population
Journal of Pharmaceutical Marketing & Management 1992; 72:17-31

HSL4351
Hardon A.
Consumers versus producers: power play behind the scenes
1992

HSL4355
Imperato JP.
Pharmaceutical advertising in the Journal
New England Journal of Medicine 1992; 327:1688

HSL4356
Ingram RA.
Some comments on direct-to-consumer advertising
Journal of Pharmaceutical Marketing & Management 1992; 7:(1):67-74

HSL4359
Kassirer JP.
Pharmaceutical advertising in the Journal
New England Journal of Medicine 1992; 327:1689

HSL4361
Kawachi I.
Where’s the bite?—Six case studies of the voluntary regulation of pharmaceutical advertising and promotion
1992269-287

HSL4362
Keith A.
The benefits of pharmaceutical promotion: An economic and health perspective
Journal of Pharmaceutical Marketing & Management 1992; 7:(1):121-133

HSL4364
Kimbel KH.
Needle money
Lancet 1992; 339:236-237

HSL4365
Krinksy DL.
Pharmaceutical ads in journals
Annals of Internal Medicine 1992; 117:618

HSL4366
Krupka LR, Vener AM.
Gender differences in drug (prescription, non-prescription, alcohol and tobacco) advertising: trends and implications
Journal of Drug Issues 1992; 22:339-360

HSL4370
Lexchin J.
Pharmaceutical promotion in the Third World
Journal of Drug Issues 1992; 22:417-453

HSL4373
Margolis LH.
Physicians' interactions with pharmaceutical companies [2nd of two letters]
Pediatrics 1992; 90:281

HSL4375
McGregor A.
Pharmaceutical industry to be taken to task
Lancet 1992; 339:1103-1104

HSL4378
Medawar C.
Power and dependence: Social Audit on the safety of medicines
: Social Audit 1992
http://www.socialaudit.org.uk/122order.htm#1.22%20How%20to%20order

HSL4379
Menkes DB.
Medical junk mail
New Zealand Medical Journal 1992; 105:437

HSL4380
Meyer DL.
Pharmaceutical company-sponsored educational activities: who benefits? who pays?
Family Medicine 1992; 24:565, 568

HSL4381
Montagne M.
Drug advertising and promotion: an introduction
Journal of Drug Issues 1992; 22:195-203

HSL4382
Montagne M.
The promotion of medications for personal and social problems
Journal of Drug Issues 1992; 22:389-405

HSL4384
Morris LA, Griffin JP.
The evolving role of FDA in prescription drug promotion
Journal of Drug Issues 1992; 22:245-256

HSL4385
Mossinghoff GJ.
Pharmaceutical manufacturers and self-regulation of drug advertising and promotion
Journal of Drug Issues 1992; 22:235-243

HSL4386
Murphy MN, Smith MC, Juergens JP.
The synergic impact of promotion intensity and therapeutic novelty on market performance of prescription drug products
Journal of Drug Issues 1992; 22:305-316

HSL4387
Myers MJ.
Marketing and pharmaceutical development
Journal of Drug Issues 1992; 22:221-234

HSL4388
Narini P.
Advertising benefits journal readers
Canadian Family Physician 1992; 38:1293

HSL4389
Newton W, Goldstein A, Frey J.
There is no such thing as a free lunch: developing policies on pharmaceutical industry support
Journal of Family Practice 1992; 34:32-34

HSL4390
Nixon AJ.
Physicians and pharmaceutical companies
Canadian Medical Association Journal 1992; 146:(328-329):

HSL4402
Novitch M.
Beware of offers of indemnity
New England Journal of Medicine 1992; 327:819

HSL4403
O’regan JB.
Physicians and pharmaceutical companies
Canadian Medical Association Journal 1992; 146:329, 332

HSL4404
Prescription drug advertisements in medical journals
1992

HSL4407
Paterson AH.
Physicians and pharmaceutical companies
Canadian Medical Association Journal 1992; 146:328

HSL4408
Payer L.
Disease-mongers: how doctors, drug companies, and insurers are making you feel sick
1992

HSL4409
Peeler CL.
Pharmaceutical advertising: A Federal Trade Commission perspective
Journal of Pharmaceutical Marketing & Management 1992; 7:(1):157-167

HSL4411
Pines WL.
Trends in health care consumer communications
Journal of Pharmaceutical Marketing & Management 1992; 7:(1):87-98

HSL4413
Reynolds WJ.
Trends in advertising pharmaceuticals: A publisher's perspective
Journal of Pharmaceutical Marketing & Management 1992; 7:(1):5-22

HSL4414
Robinson LA.
Physicians and the pharmaceutical industry
Canadian Medical Association Journal 1992; 147:5822-583

HSL4415
Rogers A.
EC pharmaceutical directives
Lancet 1992; 339:483

HSL4416
Rosenberg SJ.
Pharmaceutical promotion
New England Journal of Medicine 1992; 327:1686

HSL4418
Rubenstein DS.
Pharmaceutical ads in Annals
Annals of Internal Medicine 1992; 116:958

HSL4420
Inappropriate layout?
Canadian Family Physician 1992; 38:1769

HSL4421
Seaver PR.
Prescription drug advertising: An industry perspective
Journal of Pharmaceutical Marketing & Management 1992; 7:(1):33-41

HSL4422
Sencan N, Ãœstell I.
Information in drug advertisements
199213

HSL4424
Silverman M, Lydecker M, Lee PR.
Bad medicine: the prescription drug industry in the Third World
Stanford University Press 1992

HSL4425
Smith MC.
Future possibilities in pharmaceutical promotion
Journal of Drug Issues 1992; 22:471-480

HSL4427
Sorofman B.
Drug promotion in self-care and self-medication
Journal of Drug Issues 1992; 22:377-388

HSL4429
Squires BP.
Drug information discrepancy
Canadian Medical Association Journal 1992; 147:584, 588

HSL4430
Stallings S.
From printing press to pharmaceutical representative: a social history of drug advertising and promotion
Journal of Drug Issues 1992; 22:205-219

HSL4431
Swanson RW.
Three cheers for CME?
Canadian Medical Association Journal 1992; 146:1519

HSL4432
Taibleson DE.
Pharmaceutical advertising in the Journal
New England Journal of Medicine 1992; 327:1688

HSL4437
Tarshis GA.
Pharmaceutical promotion
New England Journal of Medicine 1992; 327:1686

HSL4438
Vandewall J.
New directions in pharmaceutical advertising
Journal of Pharmaceutical Marketing and Management 1992; 7:(1):75-86

HSL4441
Voth AJ.
Pharmaceutical ads in Annals
Annals of Internal Medicine 1992; 116:958

HSL4442
Waldholz MR.
Prescription drug advertising: A critic's perspective
Journal of Pharmaceutical Marketing & Management 1992; 7:(1):43-52

HSL4445
Watts MR, Wilkenfeld JD.
The role of the Federal Trade Commission in regulating non-prescription drug advertising and promotion
Journal of Drug Issues 1992; 22:265-276

HSL4446
Waud DR.
Pharmaceutical promotions
N Engl J Med 1992; 327:1688

HSL4452
Wilkes MS, Doblin BH, Shapiro MF.
Pharmaceutical ads in journals
Annals of Internal Medicine 1992; 117:618-619

HSL4453
Wivell MK, O’fallon DA.
Drug overpromotion: when is a warning not a warning?
Trial 1992; 28:(11):20-27

HSL4454
Woollard RF.
Physicians and pharmaceutical companies
Canadian Medical Association Journal 1992; 146:332

HSL4455
Woolley RJ.
Pharmaceutical promotion
New England Journal of Medicine 1992; 327:1687

HSL4457
Zerbe RL.
Beware of offers of indemnity
New England Journal of Medicine 1992; 327:819-820

HSL4459
ASHP policy on the acceptance of advertising.
Am J Hosp Pharm. 1992 Jan; 49:(1):160-1

HSL9054
Kanji N, Hardon A, Mamdani M, Walt G.
Drugs policy in developing countries
London: Zed Books 1992.

HSL9335
Chirac P.
Generics: neither angels nor demons
Prescrire International 1992; 1:(4):176-179

HSL9375
Koga K, Egawa N, Ohshima T, Mohri T.
Study of drug advertisements in the journals for physicians and pharmacists
Japanese Journal of Hospital Pharmacy 1992; 18:(6):661-666

HSL9380
Off-label use of medicines
Pharmaceutical Medicine 1992; 6:(4):267-271

HSL9388
Alsobrook HB.
Overview of liability for OTC drugs
Drug Information Journal 1992; 26:(3):317-328

HSL9389
Bardelay D.
Pharmaceutical industry needs to pull its socks up!
Prescrire International 1992; 1:(2):89

HSL9423
Friedman RB, Baum KL, Gable CB.
Rx to OTC conversions: role of epidemiology
Drug Information Journal 1992; 26:(2):149-154

HSL9425
Perri M, Wolfgang AP.
Consumers' cognitive and behavioral responses to health care advertising campaign
Journal of Pharmaceutical Marketing Management 1992; 6:(3):75-88

HSL19848
Sigmon JL, Anastasio GD
Drug Sample Closet
Journal of Family Practice 1992; 34:(3):262-3

HSL20231
Harrigan P
Australia: rational prescribing in general practice
The Lancet 1991 Dec 7; 338:(1448-1449):
http://www.nelm.nhs.uk/en/NeLM-Area/Evidence/Medicines-Management/References/1991---January/01/Australia--rational-prescribing-in-general-practice/

HSL4163
AAFP Congress approves statement on ethics of proprietary relationships.
Am Fam Physician. 1991 Dec 01; 44:(6):2233-9

HSL4218
Rapp MS, Woollard R.
Two cheers for the CMA's new guidelines on drug company-MD relations The CMA's MD-drug industry guidelines offer advice, nothing more.
CMAJ 1991 Dec 1; 145:(11):1497-9

HSL4232
Squires BP.
Medical journals and conflicts of interest.
CMAJ 1991 Dec 1; 145:(11):1439-40

HSL4243
Woollard R.
The CMA's MD-drug industry guidelines offer advice, nothing more.
CMAJ 1991 Dec 1; 145:(11):1498-9

HSL4169
Bayliff CD, Edington RD, Johnston LJ, Shaw PW, Bailey DG.
Impact of a pharmacist on the educational value of pharmaceutical industry film showings.
Can J Hosp Pharm 1991 Dec; 44:(6):283-7

HSL4208
Margolis LH.
The ethics of accepting gifts from pharmaceutical companies.
Pediatrics 1991 Dec; 88:(6):1233-7

HSL4221
Richards JW Jr.
AAFP white paper on proprietary relationships: just do the right thing.
Am Fam Physician 1991 Dec; 44:(6):2023

HSL4227
Schwarz RP Jr.
Maintaining integrity and credibility in industry-sponsored clinical research.
Control Clin Trials 1991 Dec; 12:(6):753-60

HSL4294
Summary of correspondence July ’90—June ’91
MaLAM Newsletter 1991 Dec

HSL4295
Drug advertisement and consumer
Drug Study Group 1991 Dec3

Page 19 of 24 pages ‹ First  < 17 18 19 20 21 >  Last ›